Literature DB >> 18443117

Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.

Ian A Critchley1, Michael R Jacobs, Steven D Brown, Maria M Traczewski, Glenn S Tillotson, Nebojsa Janjic.   

Abstract

Of 393 isolates of Streptococcus pneumoniae from U.S. children collected in 2005-2006, nonvaccine serotypes accounted for 89.1%, with serotype 19A the most prevalent, representing 30.5% of all isolates. The MIC(90) of faropenem against serotype 19A isolates was 1 mug/ml, compared to > or =8 microg/ml against amoxicillin/clavulanate, cefdinir, cefuroxime axetil, and azithromycin.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18443117      PMCID： PMC2443873          DOI： 10.1128/AAC.00310-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

Review 1.  Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment.

Authors:  D M Musher
Journal:  Clin Infect Dis       Date:  1992-04       Impact factor: 9.079

2.  American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis.

Authors: 
Journal:  Pediatrics       Date:  2000-08       Impact factor: 7.124

3.  Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media.

Authors:  M L Joloba; A Windau; S Bajaksouzian; P C Appelbaum; W P Hausdorff; M R Jacobs
Journal:  Clin Infect Dis       Date:  2001-10-04       Impact factor: 9.079

4.  Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment.

Authors:  David S Stephens; Susu M Zughaier; Cynthia G Whitney; Wendy S Baughman; Lawrence Barker; Kathryn Gay; Delois Jackson; Walter A Orenstein; Kathryn Arnold; Anne Schuchat; Monica M Farley
Journal:  Lancet       Date:  2005 Mar 5-11       Impact factor: 79.321

5.  Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine.

Authors:  J C Butler; R F Breiman; H B Lipman; J Hofmann; R R Facklam
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

6.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

7.  Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine.

Authors:  Thomas R Talbot; Katherine A Poehling; Tina V Hartert; Patrick G Arbogast; Natasha B Halasa; Ed Mitchel; William Schaffner; Allen S Craig; Kathryn M Edwards; Marie R Griffin
Journal:  Clin Infect Dis       Date:  2004-08-16       Impact factor: 9.079

8.  Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente.

Authors:  Steven Black; Henry Shinefield; Roger Baxter; Robert Austrian; Laura Bracken; John Hansen; Edwin Lewis; Bruce Fireman
Journal:  Pediatr Infect Dis J       Date:  2004-06       Impact factor: 2.129

9.  Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States.

Authors:  James A Karlowsky; Clyde Thornsberry; Ian A Critchley; Mark E Jones; Alan T Evangelista; Gary J Noel; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

10.  Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.

Authors:  Sheldon L Kaplan; Edward O Mason; Ellen R Wald; Gordon E Schutze; John S Bradley; Tina Q Tan; Jill A Hoffman; Laurence B Givner; Ram Yogev; William J Barson
Journal:  Pediatrics       Date:  2004-03       Impact factor: 7.124
View more
  6 in total

1.  Comparative antipneumococcal activities of sulopenem and other drugs.

Authors:  Klaudia Kosowska-Shick; Lois M Ednie; Pamela McGhee; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

2.  Increase in invasive Streptococcus pneumoniae infections in children with sickle cell disease since pneumococcal conjugate vaccine licensure.

Authors:  Timothy L McCavit; Charles T Quinn; Chonnamet Techasaensiri; Zora R Rogers
Journal:  J Pediatr       Date:  2010-12-28       Impact factor: 4.406

3.  Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.

Authors:  Klaudia Kosowska-Shick; Pamela McGhee; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-02-23       Impact factor: 5.191

4.  Occurrence, distribution, and origins of Streptococcus pneumoniae Serotype 6C, a recently recognized serotype.

Authors:  Michael R Jacobs; Saralee Bajaksouzian; Robert A Bonomo; Caryn E Good; Anne R Windau; Andrea M Hujer; Christian Massire; Rachael Melton; Lawrence B Blyn; David J Ecker; Rangarajan Sampath
Journal:  J Clin Microbiol       Date:  2008-10-29       Impact factor: 5.948

Review 5.  Role of Faropenem in Treatment of Pediatric Infections: The Current State of Knowledge.

Authors:  Sumitha Nayak; Uday Pai; Amita Birla
Journal:  Cureus       Date:  2022-04-25

6.  Rhinosinusitis: evidence and experience. A summary.

Authors:  Wilma T Anselmo-Lima; Eulália Sakano; Edwin Tamashiro; André Alencar Araripe Nunes; Atílio Maximino Fernandes; Elizabeth Araújo Pereira; Érica Ortiz; Fábio de Rezende Pinna; Fabrizio Ricci Romano; Francini Grecco de Melo Padua; João Ferreira de Mello; João Ferreira Mello Junior; João Teles Junior; José Eduardo Lutaif Dolci; Leonardo Lopes Balsalobre Filho; Eduardo Macoto Kosugi; Marcelo Hamilton Sampaio; Márcio Nakanishi; Marco César Jorge dos Santos; Nilvano Alves de Andrade; Olavo de Godoy Mion; Otávio Bejzman Piltcher; Reginaldo Raimundo Fujita; Renato Roithmann; Richard Louis Voegels; Roberto Eustaquio Santos Guimarães; Roberto Campos Meirelles; Roberto Campos Meireles; Rodrigo de Paula Santos; Victor Nakajima; Fabiana Cardoso Pereira Valera; Shirley Shizue Nagata Pignatari
Journal:  Braz J Otorhinolaryngol       Date:  2014-11-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.